Your browser is no longer supported. Please, upgrade your browser.
NAVB Navidea Biopharmaceuticals, Inc. weekly Stock Chart
Navidea Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.56 Insider Own31.00% Shs Outstand22.76M Perf Week5.00%
Market Cap73.41M Forward P/E- EPS next Y-0.31 Insider Trans0.06% Shs Float18.11M Perf Month-10.09%
Income-10.90M PEG- EPS next Q-0.09 Inst Own5.80% Short Float1.25% Perf Quarter-22.02%
Sales0.80M P/S91.76 EPS this Y59.90% Inst Trans67.77% Short Ratio0.58 Perf Half Y276.92%
Book/sh-0.10 P/B- EPS next Y30.20% ROA-212.50% Target Price- Perf Year224.15%
Cash/sh- P/C- EPS next 5Y- ROE667.10% 52W Range0.60 - 5.36 Perf YTD133.33%
Dividend- P/FCF- EPS past 5Y30.80% ROI843.30% 52W High-47.64% Beta1.92
Dividend %- Quick Ratio1.50 Sales past 5Y-36.30% Gross Margin99.80% 52W Low367.50% ATR0.24
Employees13 Current Ratio1.50 Sales Q/Q0.00% Oper. Margin- RSI (14)37.55 Volatility5.40% 7.58%
OptionableYes Debt/Eq- EPS Q/Q56.20% Profit Margin- Rel Volume0.24 Prev Close2.94
ShortableYes LT Debt/Eq- EarningsAug 13 AMC Payout- Avg Volume387.34K Price2.81
Recom2.00 SMA20-4.14% SMA50-23.64% SMA20034.67% Volume91,325 Change-4.59%
Nov-13-13Reiterated Aegis Capital Hold $3 → $2
Nov-07-13Reiterated Ladenburg Thalmann Buy $7.50 → $3
Jan-24-13Initiated Burrill Institutional Research Mkt Outperform $5
Jan-22-13Initiated Aegis Capital Hold $3
Sep-11-12Reiterated WBB Securities Strong Buy $9 → $7
Sep-11-12Reiterated Rodman & Renshaw Mkt Outperform $7 → $6
Sep-11-12Reiterated Ladenburg Thalmann Buy $6.25 → $7.50
Sep-08-20 04:05PM  
Sep-02-20 04:05PM  
Aug-31-20 05:00PM  
Aug-24-20 04:05PM  
Aug-13-20 04:09PM  
Aug-10-20 09:08AM  
Aug-06-20 04:15PM  
Aug-05-20 07:30AM  
Jun-25-20 03:50AM  
Jun-17-20 09:43AM  
Jun-15-20 08:00AM  
Jun-09-20 07:30AM  
Jun-03-20 07:30AM  
May-26-20 10:11AM  
May-22-20 08:35AM  
May-21-20 04:30PM  
May-14-20 04:01PM  
May-11-20 07:30AM  
May-07-20 07:00AM  
Apr-22-20 07:30AM  
Apr-21-20 08:52AM  
Mar-31-20 07:30AM  
Mar-24-20 04:19PM  
Mar-20-20 07:00AM  
Mar-11-20 04:05PM  
Mar-04-20 08:00AM  
Feb-21-20 08:42AM  
Feb-14-20 11:56AM  
Feb-12-20 09:20AM  
Dec-30-19 05:19PM  
Dec-14-19 09:41AM  
Dec-06-19 06:23PM  
Dec-05-19 03:45PM  
Dec-02-19 02:08PM  
Nov-19-19 10:41PM  
Nov-14-19 08:30AM  
Nov-13-19 07:38AM  
Nov-07-19 04:05PM  
Oct-31-19 07:30AM  
Oct-29-19 07:30AM  
Oct-14-19 03:42PM  
Sep-06-19 04:05PM  
Aug-27-19 07:30AM  
Aug-08-19 04:05PM  
Aug-01-19 04:05PM  
Jun-24-19 07:46AM  
Jun-18-19 04:05PM  
Jun-17-19 05:16PM  
Jun-13-19 11:16PM  
May-08-19 06:28PM  
May-01-19 04:05PM  
Apr-26-19 07:30AM  
Apr-19-19 04:05PM  
Apr-08-19 07:30AM  
Apr-02-19 04:05PM  
Mar-22-19 05:08PM  
Mar-13-19 01:31PM  
Mar-07-19 04:05PM  
Feb-28-19 07:00AM  
Feb-01-19 07:00AM  
Jan-24-19 07:00AM  
Dec-07-18 06:55AM  
Dec-04-18 12:17AM  
Nov-29-18 04:35PM  
Nov-28-18 06:55AM  
Nov-27-18 06:55AM  
Nov-26-18 04:30PM  
Nov-15-18 07:40AM  
Nov-07-18 06:45PM  
Nov-01-18 07:00AM  
Oct-31-18 05:30PM  
Oct-30-18 04:30PM  
Oct-11-18 06:55AM  
Oct-08-18 05:00PM  
Sep-18-18 08:44AM  
Sep-17-18 05:30PM  
Sep-04-18 10:24AM  
Aug-16-18 03:00PM  
Aug-15-18 05:47PM  
Aug-08-18 07:05PM  
Jul-12-18 05:47PM  
Jun-14-18 05:37PM  
May-30-18 04:30PM  
May-17-18 09:42PM  
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. In addition, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. Further, the company is developing diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a preclinical therapeutic research collaboration with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scott John K Jr.10% OwnerAug 30Buy5.005,00025,0008,047,162Sep 02 09:47 PM
Latkin JedCEO, COO & CFOFeb 20Buy1.085,0005,40017,950Feb 20 04:39 PM
Scott John K Jr.10% OwnerFeb 13Buy0.852,373,5292,017,5008,042,162Feb 19 03:58 PM
Scott John K Jr.10% OwnerDec 06Buy0.90555,555500,0005,668,633Dec 11 11:11 AM